To Market Or Not To Market? Roche Fights Amgen Patent Litigation
This article was originally published in Pharmaceutical Approvals Monthly
While FDA's review of the Mircera BLA offers a focal point for the agency's battle to keep ESA labeling abreast of ESA science, the Mircera molecule itself may not see the U.S. market.
You may also be interested in...
With FDA’s review of Roche’s Mircera BLA, the agency went beyond the normal evaluation leading to approval of the drug; it seized the opportunity to weigh in on the proper development of erythropoiesis-stimulating agents.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011